STAT | Reporting from the frontiers of health and medicine Follow STAT+: Novo Nordisk to buy Akero Therapeutics, picking up promising MASH drug Novo Nordisk is buying Akero Therapeutics, the maker of a promising MASH drug, in a deal worth $4.7 billion upfront https://www.statnews.com/2025/10/09/novo-nordisk-mash-liver-akero-acquistion-efruxifermin/ statnews.com
